Wedbush Reiterates Outperform on Blueprint Medicines, Maintains $110 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten reiterates an Outperform rating on Blueprint Medicines (NASDAQ:BPMC) and maintains a $110 price target.
April 26, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten reaffirmed an Outperform rating on Blueprint Medicines with a $110 price target.
The reaffirmation of the Outperform rating and the maintenance of a $110 price target by a reputable analyst could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100